fredric n eshelman pharmd executive profile  biography  bloomberg july    am et pharmaceuticals company overview of innocrin pharmaceuticals inc snapshotpeople  overviewboard memberscommittees executive profile fredric n eshelman pharmdchief executive officer and director innocrin pharmaceuticals incagetotal calculated compensationthis person is connected to  board members in  different organizations across  different industriessee board relationships background dr fredric n eshelman also known as fred pharmd has been the chief executive officer of innocrin pharmaceuticals inc since march   dr eshelman is the founder and principal of eshelman ventures llc dr eshelman served as the chief executive officer and executive chairman of pharmaceutical product development inc from july   to july  he served as an executive chairman of furiex pharmaceutical inc dr eshelman founded pharmaceutical product  development incs predecessor and served as the chief executive officer until  he served as the senior vice president development of glaxo inc and held various roles in drug development with other pharmaceutical companies such as beecham laboratories and boehringer mannheim pharmaceuticals he has been the nonexecutive chairman of the medicines company since august   he has been the founding chairman of furiex pharmaceuticals inc since  and has been its director since october  he served as vice chairman of pharmaceutical product development from july  to july  and its director since july  he has been an independent director of valeant pharmaceuticals international inc since march   he serves as the director at asepticys inc he has been a director of g therapeutics inc since february   and innocrin pharmaceuticals inc since april   he serves on a number of industry boards including the association of clinical research organizations he is a member of advisory board of auven therapeutics management lllp and princeton biopharma capital partners llc most recently he was appointed chairman of the medicines company dr eshelman serves as a director of meryx inc he serves on the board of visitors for the school of pharmacy at the university of north carolina in addition he chairs the board of visitors for the school of pharmacy at uncch he served as a director of spotlight health inc and takeda california inc dr eshelman served as a director of glaxo inc from  to  and served as a director of accelerator corporation and takeda san diego inc dr eshelman served as a director of primecyte inc and aton pharma inc he was on the board of trustees for uncw and in  was appointed by the nc general assembly to serve on the board of governors for the state’s multicampus university system as well as the nc biotechnology center he has received many awards including the davie and distinguished service awards from unc nc entrepreneur hall of fame award and outstanding alumnus from both the unc and university of cincinnati schools of pharmacy he has a doctorate of pharmacy from the university of cincinnati and a bs in pharmacy from the university of north carolina at chapel hill in  and a graduate of the owner president management program at harvard business schoolread full background corporate headquarters  emperor boulevarddurham north carolina united statesphone fax  board members memberships directormeryx incdirectorasepticys incpresentfounding chairmanfuriex pharmaceuticals incpresentnonexecutive chairmanthe medicines companypresentdirectorg therapeutics incpresentchief executive officer and directorinnocrin pharmaceuticals incpresentindependent directorvaleant pharmaceuticals international inc education bs university of north carolina at chapel hilldoctorate university of cincinnati other affiliations the medicines companypharmaceutical product development llctakeda california incspotlight health incvaleant pharmaceuticals international incuniversity of north carolina at chapel hillprimecyte incaton pharma incuniversity of cincinnatiaccelerator corporationabcro incauven therapeutics management lllpfuriex pharmaceuticals incg therapeutics incprinceton biopharma capital partners llcmeryx inceshelman ventures llcasepticys inc annual compensation there is no annual compensation data available stocks options there is no stock options data available total compensation there is no total compensation data available request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup competitor compensationthere is no competitor compensation data available sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact innocrin pharmaceuticals inc please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close equilar atlas seo  page not available    log in  sign up page not available please click here to continue browse individual profiles  a  b  c  d  e  f  g  h  i  j  k  l  m  n  o  p  q  r  s  t  u  v  w  x  y  z �  equilar inc    about    terms of use    executive rankings   fredric n eshelman  ceo founder businessman  profile directorpedianet  list of ceos founders board members and company directors fredric n eshelman check out list of companies and businesses related to fredric n eshelman find out fredric n eshelman address and contact details view other people related to fredric n eshelman  coworkers colleagues companions etc address  towles road wilmington  nc companies related to fredric n eshelman cikcompany namepositioncompany addressvaleant pharmaceuticals international incdirector  st elzear blvd west laval quebec hl apharmaceutical product development incceo  north front street wilmington medicines co dedirector  sylvan way parsippany g therapeutics incdirector  tw alexander drive  research commons suite  research triangle park  fredric n eshelman on the web persons related to fredric n eshelman  valeant pharmaceuticals international incnamepositioncitychristina ackermannevp and general counsel bridgewaterwilliam a ackmannew yorkthomas appioevp company group chairman bridgewaterrobert roswell chaionnevp clo general counsel mississaugarobert roswell chaionnevp gc  corp sec mississaugarobert roswell chaionnevp gen couns and corp sec montrealrobert roswell chaionnmontrealrobert roswell chaionnevp gen couns  corp sec montrealrobert roswell chaionnmontrealrobert roswell chaionnevp gen couns  corp sec lavalrobert roswell chaionnevp gen couns  corp secy lavalmichel chouinardmississaugamichel chouinardcoo biovail labs intl srl mississaugamichel chouinardcoo biovail labsintl srl worthing christ churchmichel chouinardcoo biovail labs intl srl mississaugamichel chouinardcoo biovail labs intl srl mississaugaschutter richard u dedirector palo altosilva rajiv depresident  coo mississaugasilva rajiv depresident  coo spec pharma mississaugasilva rajiv depresidentvpiicoospecpharma mississaugasilva rajiv depresident  coo mississaugasilva rajiv depresident and coo montrealsilva rajiv depresident  coo montrealmark andrew durhamsenior vp hr  shared svs mississaugamark andrew durhamsvp hr  shared services mississaugamark andrew durhamsvp hr  shared services mississaugamark andrew durhamsvp human resources mississaugamark andrew durhamsvp human resources mississaugasam eldessoukysvp chief accounting officer princetonfredric n eshelmandirector wilmingtonronald harold farmerdirector mississaugaronald harold farmerdirector montrealronald harold farmerdirector lavalhans christian fibigermississaugahans christian fibigerchief scientific officer mississaugahans christian fibigerchief scientific officer mississaugahans christian fibigerchief scientific officer mississaugahans christian fibigerchief scientific officer mississaugastephen fraidinnew yorkgilbert godinexecutive vicepresident  coo mississaugagilbert godinevp  coo mississaugagilbert godinevp  coo mississaugacolleen a gogginsdirector new brunswickcolleen a gogginsdirector bridgewaterserge gouinmississaugaserge gouindirector mississaugagregory david gubitzmississaugagregory david gubitzsenior vice president  gc mississaugagregory david gubitzsvp corp devel  gc mississaugadavid robert haledirector san franciscosusan hallglobal head of rd mississaugasusan hallglobal head of rd montrealsusan hallglobal head of rd montrealsusan hallglobal head of rd lavaljason david hansonevp company group chairman montrealfred hassandirector lavalpaul herendeenevp and cfo rockawaywilliam d humphriesevp company group chairman alpharettarobert a ingramdirector robert alexander ingramdirector mississaugarobert alexander ingramdirector mississaugarobert alexander ingramdirector mississaugarobert alexander ingramdirector montrealrobert alexander ingramdirector lavaldebora jornevp company group chairman bridgewaterargeris n karabelasdirector san diegosarah b kavanaghdirector lavalari kellenevp company group chairman bridgewaterari kellenevp company group chairman bridgewaterari kellenevp company group chairman bridgewaterlaizer kornwasserevp company group chairman franklin lakeslaizer kornwasserevp company group chairman montreallaizer kornwasserevp company group chairman lavallaizer kornwasserevp company group chairman bridgewaterlaizer kornwasserbridgewaterlaizer kornwasserevp company group chairman bridgewaterlaizer kornwasserevp company group chairman bridgewaterdavid h laidleydirector mississaugadavid h laidleydirector mississaugajohn spencer lanthiermississaugajohn spencer lanthierdirector mississaugaphilip walden loberg jrevp interim cfo mississaugaphilip walden loberg jrevp interim cfo mississaugaanders lonnerdirector aliso viejoanders lonnerdirector bridgewaterrichard kevin mastersonprescoovaleant intbbsrl mississaugarichard kevin mastersonpres  coo valeant int bb mississaugarichard kevin mastersonpres  coo valeant intl bb montrealchristine mayersvp bta pharmaceuticals inc mississaugachristine mayersvp bta pharmaceuticals inc mississaugachristine mayersvp bta pharmaceuticals inc mississaugakyriazi theo melasdirector kyriazi theo melasdirector mississaugakyriazi theo melasdirector mississaugakyriazi theo melasdirector montrealkyriazi theo melasdirector lavalpavel mirovskyevp pres  gm valeant emena lavalg mason morfitdirector san franciscomargaret jean mulliganmississaugamargaret jean mulligansvp  cfo mississaugamargaret jean mulliganevp cfo mississaugajoseph c papachairman  ceo coronamark w parrishdirector mississaugamark w parrishdirector mississaugalaurence e pauldirector mississaugalaurence e pauldirector mississaugalaurence e pauldirector mississaugalaurence e pauldirector mississaugalaurence e pauldirector mississaugalaurence e pauldirector montrealjohn paulsondirector new yorkj michael pearsonchief executive officer aliso viejoj michael pearsonmississaugaj michael pearsonchief executive officer mississaugaj michael pearsonchief executive officer mississaugaj michael pearsonchief executive officer mississaugaj michael pearsonchief executive officer montrealj michael pearsonmontrealj michael pearsonchief executive officer lavalpershing square capital management lpdirector new yorkfrank pottermississaugafrank potterdirector mississaugarobert n powerdirector madisonrobert n powermississaugarobert n powerdirector mississaugarobert n powerdirector mississaugarobert n powerdirector montrealrobert n powerdirector lavalrobert n powermontrealnorma ann provenciodirector covinanorma ann provenciodirector mississauganorma ann provenciodirector mississauganorma ann provenciodirector mississauganorma ann provenciodirector montrealnorma ann provenciodirector lavalps management gp llcnew yorkrussel c robertsondirector bridgewaterrobert l rosielloevp corp dev  strategy bridgewaterthomas w sr rossdirector bridgewaterhoward bradley schillerchairman and ceo mississaugahoward bradley schillerevp and cfo mississaugahoward bradley schillerevp and cfo montrealhoward bradley schillerevp and cfo montrealhoward bradley schillerevp and cfo lavalhoward bradley schillerchief financial officer lavallloyd mitchell segalmississaugalloyd mitchell segaldirector mississaugalloyd mitchell segaldirector mississaugalloyd mitchell segaldirector mississaugalloyd mitchell segaldirector montreallloyd mitchell segaldirector lavaldouglas john paul squiresmississaugadouglas john paul squiresdirector mississaugakatharine berghuis stevensondirector bramptonkatharine berghuis stevensondirector montrealkatharine berghuis stevensondirector lavalkatharine berghuis stevensondirector lavalkatharine berghuis stevensondirector lavalkatharine berghuis stevensondirector mississaugakatharine berghuis stevensondirector mississaugakatharine berghuis stevensondirector mississaugabrian m stolzevp administration  chco mississaugabrian m stolzevp administration and chco mississaugabrian m stolzevp administration and chco montrealbrian m stolzevp administration  chco montrealbrian m stolzevp administration and chco montrealbrian m stolzevp administration and chco lavallouis randall tullmississaugalouis randall tulldirector mississaugajeffrey w ubbendirector jeffrey w ubbendirector san franciscova partners i llcsan franciscova partners i llcsan franciscovalueact capital management lpsan franciscovalueact capital management lpsan franciscovalueact capital management llcsan franciscovalueact capital management llcsan franciscovalueact capital master fund lpsan franciscovalueact capital master fund lpsan franciscovalueact coinvest master fund lpsan franciscovalueact coinvest master fund lpsan franciscovalueact holdings gp llcsan franciscovalueact holdings gp llcsan franciscovalueact holdings lpdirector san franciscovalueact holdings lpdirector san franciscoevery michael robert vanmississaugaevery michael robert vandirector mississaugaevery michael robert vandirector mississaugaevery michael robert vandirector mississaugaamy b wechslerdirector bridgewaterdaniel mark wechslerevo co grp chmn eye health lavalryan weldonevp company group chairman montrealryan weldonevp company group chairman lavalryan weldonevp company group chairman lavalwilliam mcdowall wellschief executive officer mississaugawilliam mcdowall wellschief executive officer mississaugawilliam mcdowall wellsdirector mississaugawilliam mcdowall wellsdirector mississaugaanne clem whitakerevp company group chairman durhampersons related to fredric n eshelman  pharmaceutical product development incnamepositioncitylee babissexec vpglobal lab services wilmingtonlinda baddourchief financial officer wilmingtonlinda baddourchief financial officer wilmingtonlinda baddourformer chief financial officer wilmingtonstuart bondurantdirector chapel hillvaughn d brysondirector wilmingtonfrancis j casierisr vp global business dev wilmingtonpaul colvinevpclinical development wilmingtonpaul s covingtonexecutive vice president wilmingtondaniel g darazsdichief financial officer wilmingtondaniel g darazsdiwilmingtonfred b davenport jrpresident wilmingtonchristine a dingivanevpchief medical officer wilmingtonchristine a dingivanwilmingtonfredric n eshelmanceo wilmingtonfredric n eshelmanexecutive chairman wilmingtonmarye anne foxdirector raleighmarye anne foxdirector la jollafred frankdirector new yorkdavid l grangedirector wheatondavid l grangechief executive officer wilmingtonjudd hartmangeneral counsel wilmingtonjudd hartmangeneral counsel wilmingtonraymond h hillchief executive officer wilmingtonraymond h hillchief executive officer wilmingtonrobert alexander ingramdirector wilmingtoncathy klemadirector new yorkcathy klemadirector new yorkterry magnusondirector chapel hillernest mariodirector palo altoernest mariodirector princetonjohn a mcneill jrdirector whitevillewilliam w richardsonsr vp global bus development raleighwilliam w richardsonsr vp global bus development wilmingtoncolin shannonnew marketcolin shannonevp global clinical ops new market ukcolin shannonevp global clinical ops wilmingtonwilliam j sharbaughchief operating officer wilmingtonwilliam j sharbaughwilmingtonralph snydermandirector wilmingtonw richard staubsr vice president raleighmichael o wilkinsonwilmingtonmichael o wilkinsonchief information officer wilmingtonpeter j wilkinsonvp of finchief acctg off wilmingtonpeter j wilkinsonvp of finchief acctg off wilmingtonpersons related to fredric n eshelman  medicines co denamepositioncitypaul michael antinoriparsippanypaul michael antinorisvp and general counsel parsippanypaul michael antinorisvp and general counsel parsippanypaul michael antinorisr vp  general counsel parsippanyleonard bellleonard belldirector cheshirechristopher t coxevp  chief corp dev officer chelmsfordwilliam crousedirector william crousedirector princetonwilliam crousedirector parsippanywilliam crousedirector parsippanywilliam crousedirector parsippanydeerfield capital lpnew yorkdeerfield international ltdtortolamanagement co ny deerfieldnew yorkdeerfield partners lpnew yorkalexander j dennerdirector greenwichfredric n eshelmandirector wilmingtonjames e flynn owner new yorkjeff frazierevp chief human strategy parsippanybrent furseevp chief customer officer parsippanycornelis heimanevp chief innovation officer parsippanyrobert j hugindirector robert j hugindirector parsippanyrobert j hugindirector parsippanyrobert j hugindirector parsippanyrobert j hugindirector parsippanyt scott johnsont scott johnsondirector parsippanyt scott johnsondirector parsippanyt scott johnsondirector parsippanyt scott johnsondirector parsippanyt scott johnsondirector parsippanyt scott johnsondirector parsippanyjohn p kelleypresident and coo parsippanyjohn c kellydirector madisonjohn c kellydirector parsippanyjohn c kellyparsippanyarmin m kesslerdirector armin m kesslerdirector parsippanyarmin m kesslerdirector parsippanyarmin m kesslerdirector parsippanystuart a kingsleypresident and coo marlboroughsteven h koehlersenior vice president and cfo parsippanysteven h koehlersenior vice president and cfo parsippanyvictoria kusiakevp chief integrity officer parsippanyclive meanwellceo clive meanwellchief executive officer parsippanyclive meanwellchief executive officer parsippanyclive meanwellchief executive officer parsippanyclive meanwellchairman  ceo parsippanycatharine s newberrysenior vice president parsippanywilliam bernard oconnorchief financial officer parsippanywilliam bernard oconnorsr vp  chief acct officer parsippanywilliam bernard oconnorchief accounting officer parsippanyparis panayiotopoulosdirector cambridgejohn d richardsvice president parsippanyjohn d richardsvice president parsippanystephen m rodinevp and general counsel parsippanyleslie c rohrbackervp chief human strategy offic parsippanyrobert g savagedirector robert g savagedirector parsippanyrobert g savagedirector parsippanyrobert g savagedirector parsippanyrobert g savagedirector parsippanyrobert g savagedirector parsippanyglenn sblendoriopresident  cfo new yorkglenn sblendorioexecutive vice president parsippanyglenn sblendorioexecutive vice president parsippanyglenn sblendoriopresident  cfo parsippanyhiroaki shigetadirector parsippanyhiroaki shigetadirector parsippanymelvin k spigelmandirector parsippanymelvin k spigelmandirector parsippanydavid m stackdavid m stackpresident and chief executive parsippanypeter teuberpeter teubervice president parsippanyjames e thomasdirector pacicco kelli watsonsenior vice president parsippanyelizabeth h s wyattdirector elizabeth h s wyattdirector parsippanyelizabeth h s wyattdirector parsippanypersons related to fredric n eshelman  g therapeutics incnamepositioncitywebb carolchapel hillwebb carolchapel hillwebb carolchapel hillwebb carolresearch triangle parkshaffer christychapel hillshaffer christychapel hillshaffer christyresearch triangle parkblack claudiachapel hillthorp claychapel hillthorp claychapel hillthorp clayresearch triangle parkjohn crumplerdurhamfredric n eshelmandirector wilmingtoneshelman ventures llc owner research triangle parkeshelman fredericresearch triangle parkmuir glennresearch triangle parkmossinghoff gregoryresearch triangle parkhatteras venture advisors iv sbic llcdurhamhatteras venture partners iv sbic lpdurhamrobert a ingramstaun jaychapel hillstrum jaychapel hillstrum jaychapel hillstrum jayresearch triangle parkpeter kolchinskybostonwong kwokkinarlingtonkenneth b lee jrrajesh malikresearch triangle parkvelleca markresearch triangle parkmedimmune ventures inc owner gaithersburggutch michaelresearch triangle parkjennifer k mosesresearch triangle parkgregory j mossinghoffdurhamglenn p muirdirector sharpless normanchapel hillsharpless normanchapel hillsharpless normanchapel hillsharpless normanresearch triangle parkkolchinsky peterresearch triangle parkra capital biotech fund lpbostonra capital management llc bostondouglas md reeddeerfieldtyrell riversresearch triangle parklaufer ronresearch triangle parkseth rudnickdirector rowaytonrudnick sethresearch triangle parkchristy l shafferdirector jay strumchief scientific officer research triangle parktimothy eugene sullivanresearch triangle parklaundon thomaschapel hilllaundon thomaschapel hilllaundon thomasresearch triangle parkclay thorp owner durhamsullivan timothyresearch triangle parkmark a vellecaresearch triangle parkandrew wittydirector research triangle park   mdco fredric n eshelman insider trades for medicines co bulletin investor alert london markets open in asia markets currencies us market snapshot expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close medicines co nasdaq mdco go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus medicines co after hours  quotes are delayed by  min jul    pm mdco quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite previous close     change   day low day high    week low  week high   insider activity individual fredric n eshelman dr fredric n eshelman is a director at accelerator corp and founder at eshelman ventures llc he is on the board of directors at the medicines co aton pharma inc g therapeutics inc innocrin pharmaceuticals inc xori corp and north carolina school of science  mathematics dr eshelman was previously employed as a principal by boehringer mannheim pharmaceuticals corp founding chairman by furiex pharmaceuticals inc senior vice president  director by glaxo inc chief executive officer  executive chairman by pharmaceutical product development llc and a trustee by university of north carolina at wilmington he received his undergraduate degree from the university of north carolina at chapel hill and a doctorate degree from the university of cincinnati ohio transactions date shares transaction value     award at  per share      acquisition at  per share      acquisition at  per share      acquisition at  per share      acquisition at  per share      acquisition at  per share      award at  per share      acquisition at  per share  copyright  factset research systems inc all rights reserved source factset fundamentals officers and executives dr fredric n eshelman nonexecutive chairman mr stuart anthony kingsley president  chief operating officer dr clive a meanwell chief executive officer  director mr william bernard oconnor svp chief financial  accounting officer dr david kallend vice president  global medical director mr christopher t cox chief corporate development officer  evp mr gregory moeck headinfectious disease biology dr michael n dudley senior vice president  headhealth science mr robert werner vice presidentvalue  market access ms tanya quinn senior directorglobal distribution dr stephanie plent evp  headglobal health economics dr john w villiger executive vice president dr bruce r rosengard vice presidentnew business ventures mr jeffrey a frazier chief human strategy officer  executive vp mr mike mcguire infectious disease pathway leader mr ray russo vice presidentglobal chest pain pathway mr anthony flammia vice president  gmmergers  acquisitions mr paris panayiotopoulos director ms margaret langan vice presidentmedia relations dr krishna gorti vice presidentinvestor relations dr nancye green executive vice presidentglobal communications mr bob laverty vice presidentcommunications mr stephen m rodin secretary senior vice president  general counsel dr loretta m itri evpglobal health science  regulatory affairs dr alexander john denner independent director mr william w crouse independent director mr armin m kessler independent director dr elizabeth hamilton seabury wyatt lead independent director dr melvin k spigelman independent director mr john c kelly independent director mr robert j hugin independent director mr hiroaki shigeta independent director trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite tlt quoteszigmancomposite jnug x powered by log in  am edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest atrump to make statement on healthcare monday reports areckitt benckiser profit rises on reduced costs achinese regulator tells insurers to shape up arandgold looks to get more out of tongon mine aryanair profit soars  warns on overcapacity asiemens and bombardier in talks to form train jvs avw asks eu to scrutinize german car makers akkr close to announcing deal for webmd ajulius baer assets under management jump aroyal philips profit rises begins share buybacks aryanair profit rises  beating expectations ahow opec committee’s coming meeting could make or break oil prices aoil prices steady with all eyes on opec meeting ajapan aussie stocks knocked by weak dollar commodity prices aimf cuts us growth forecast for   p‘game of thrones’ the four biggest takeaways from stormborn’ pwhy you’re more likely to die in an accident during the summer months pthese wealthy parents spend  for summer camps so their kids can be ‘normal’ p totally avoidable reasons why millennials can’t have nice things or save any money phow elon musk and shorter commutes could transform people’s lives loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  insider trading history of eshelman fredric n at g therapeutics inc insider monitor realtime insider buys insider buys today     insider buys  day ago insider buys  days ago insider buys  days ago insider buys  days ago insider buys  days ago insider buys  days ago insider buys  days ago insider buys  days ago insider buys  days ago insider buys  days ago insider sales insider sales today       insider sales  day ago insider sales  days ago insider sales  days ago insider sales  days ago insider sales  days ago insider sales  days ago insider sales  days ago top  top  insider buys of the week top  officer buys of the week top  insider buys of the month top  officer buys of the month top  insider sales of the week top  insider sales of the month               insider stock trading history of eshelman fredric n the following table details the trading activities stock purchases stock sales and stock option exercises reported to the securities and exchange commission sec by insider eshelman fredric n since year  the traders cik number is  at the time of this reporting eshelman fredric n is the director of g therapeutics inc  stock ticker symbol gthx see this page for all insider trading activities at g therapeutics inc  note that in the past eshelman fredric n also reported insider trading activities as an insider of the following companies insider activities at g therapeutics inc gthx insider activities at medicines co de mdco insider activities at furiex pharmaceuticals inc furx insider activities at pharmaceutical product development inc ppdi stock purchases sales and option exercises reported by insider eshelman fredric n since    trade date   symbol company name issuer trade type     shares       price    value   gthx g therapeutics inc buy     mdco medicines co de buy     mdco medicines co de buy     mdco medicines co de buy     mdco medicines co de buy     furx furiex pharmaceuticals inc option ex     furx furiex pharmaceuticals inc buy     furx furiex pharmaceuticals inc buy     furx furiex pharmaceuticals inc buy     furx furiex pharmaceuticals inc buy     furx furiex pharmaceuticals inc buy     furx furiex pharmaceuticals inc buy     furx furiex pharmaceuticals inc buy     furx furiex pharmaceuticals inc buy     furx furiex pharmaceuticals inc buy     furx furiex pharmaceuticals inc buy     furx furiex pharmaceuticals inc buy     furx furiex pharmaceuticals inc buy     furx furiex pharmaceuticals inc buy     furx furiex pharmaceuticals inc buy     furx furiex pharmaceuticals inc buy     furx furiex pharmaceuticals inc buy     furx furiex pharmaceuticals inc buy     furx furiex pharmaceuticals inc buy     furx furiex pharmaceuticals inc buy     furx furiex pharmaceuticals inc buy     furx furiex pharmaceuticals inc option ex     furx furiex pharmaceuticals inc buy     furx furiex pharmaceuticals inc buy     furx furiex pharmaceuticals inc buy     furx furiex pharmaceuticals inc buy     furx furiex pharmaceuticals inc buy     furx furiex pharmaceuticals inc buy     furx furiex pharmaceuticals inc buy     furx furiex pharmaceuticals inc buy     furx furiex pharmaceuticals inc buy     furx furiex pharmaceuticals inc buy     furx furiex pharmaceuticals inc buy     furx furiex pharmaceuticals inc buy     furx furiex pharmaceuticals inc buy     furx furiex pharmaceuticals inc buy     furx furiex pharmaceuticals inc buy     furx furiex pharmaceuticals inc buy     furx furiex pharmaceuticals inc buy     furx furiex pharmaceuticals inc buy     furx furiex pharmaceuticals inc buy     furx furiex pharmaceuticals inc buy     ppdi pharmaceutical product development inc sale     ppdi pharmaceutical product development inc sale     ppdi pharmaceutical product development inc sale     ppdi pharmaceutical product development inc sale     ppdi pharmaceutical product development inc sale     ppdi pharmaceutical product development inc sale     ppdi pharmaceutical product development inc sale     ppdi pharmaceutical product development inc sale     ppdi pharmaceutical product development inc sale     ppdi pharmaceutical product development inc sale     ppdi pharmaceutical product development inc sale     ppdi pharmaceutical product development inc sale     ppdi pharmaceutical product development inc sale     ppdi pharmaceutical product development inc sale     ppdi pharmaceutical product development inc sale     ppdi pharmaceutical product development inc sale     ppdi pharmaceutical product development inc sale     ppdi pharmaceutical product development inc sale     ppdi pharmaceutical product development inc sale     ppdi pharmaceutical product development inc sale     ppdi pharmaceutical product development inc sale     ppdi pharmaceutical product development inc sale     ppdi pharmaceutical product development inc sale     ppdi pharmaceutical product development inc sale     ppdi pharmaceutical product development inc sale     ppdi pharmaceutical product development inc sale     ppdi pharmaceutical product development inc sale     ppdi pharmaceutical product development inc sale     ppdi pharmaceutical product development inc sale     ppdi pharmaceutical product development inc sale     ppdi pharmaceutical product development inc sale     ppdi pharmaceutical product development inc sale     ppdi pharmaceutical product development inc sale     ppdi pharmaceutical product development inc sale     ppdi pharmaceutical product development inc sale     ppdi pharmaceutical product development inc sale     ppdi pharmaceutical product development inc sale     ppdi pharmaceutical product development inc sale     ppdi pharmaceutical product development inc sale     ppdi pharmaceutical product development inc sale     ppdi pharmaceutical product development inc sale     ppdi pharmaceutical product development inc sale     ppdi pharmaceutical product development inc sale     ppdi pharmaceutical product development inc sale    insider trading activities including stock purchases stock sales and option exercises listed in the above table cannot be completely guaranteed as to their accuracy for more information regarding the trades made by eshelman fredric n director of g therapeutics inc at the time of this reporting see the securities and exchange commission sec website newest insider buys insider trading resources archive privacy contact  market holidays market hours tweet  insidermonitorcom all rights reserved   dr fredric n eshelman files preliminary written consent statement in connection with puma biotechnology inc  business wire dr fredric n eshelman files preliminary written consent statement in connection with puma biotechnology inc october    pm eastern daylight time new yorkbusiness wiredr fredric n eshelman today filed a preliminary consent statement with the securities and exchange commission in connection with his proposed solicitation of written consents from the holders of shares of common stock of puma biotechnology inc dr eshelman is the beneficial owner of approximately  percent of the issued and outstanding shares of puma common stock dr eshelman’s preliminary consent statement includes proposals to increase the size of the board of directors of puma from five to nine directors and to elect as new directors dr eshelman and three other highly qualified candidates james m daly seth a rudnick md and kenneth b lee jr dr eshelman has more than  years of strategic development executive operational and financial leadership experience in the pharmaceutical and healthcare industries he is currently nonexecutive chairman of the medicines company and previously founded pharmaceutical product development inc “ppd” and furiex pharmaceuticals inc “furiex” in  dr eshelman founded eshelman ventures llc an investment company focused on healthcare companies dr eshelman also serves on the boards of directors of several privately held companies including aeromd cellective biotherapy inc dignify therapeutic inc eyenovia inc g therapeutics inc innocrin pharmaceuticals inc medikidz usa inc meryx inc and neoantigenics llc and on the advisory board of auven therapeutics james m daly served as executive vice president and chief commercial officer at incyte corporation a biopharmaceutical company from october  until june  and has served as a director of chimerix inc a privately held biotechnology company since  prior to joining incyte mr daly served as senior vice president of north america commercial operations and global marketingcommercial development at amgen inc a global pharmaceutical company prior to his employment with amgen mr daly was senior vice president and general manager of the respiratoryantiinfective business unit at glaxosmithkline seth a rudnick md is currently chairman of several privately held biotechnology companies including meryx pharmaceuticals liquidia technologies inc and g therapeutics dr rudnick also serves on the board of square  a public company previously dr rudnick was the chief executive officer and chairman of cytotherapeutics inc a company developing stem cellbased therapies in addition he helped found and served as the head of research and development for ortho biotech a division of johnson  johnson focusing on cancer and chronic illnesses dr rudnick is a clinical adjunct professor of medicine at university of north carolina chapel hill kenneth b lee jr is a managing member of hatteras biocapital llc and the general partner of hatteras biocapital fund lp a venture capital fund focusing on life sciences companies currently mr lee serves on the boards of directors of the following publicly held companies biocryst pharmaceuticals inc and pozen inc for which he serves as lead director chairman of the compensation committee and as a member of the audit committee mr lee also serves on the board of two private companies clinverse inc and clinipace worldwide inc for which he serves as chairman and is a cofounder of the national conference on biotechnology venture between  and  mr lee served on the boards of directors of several public companies maxygen inc osi pharmaceuticals inc cv therapeutics inc abgenix inc and inspire pharmaceuticals inc mr lee was formerly national director of the life science practice at ernst and young llp where he advised biotechnology and pharmaceutical companies throughout the world on a wide range of financial and strategic planning issues mr lee received a ba from lenoirrhyne college and an mba from the university of north carolina at chapel hill the proposals contained in the consent statement will be effective without further action by puma or its board when dr eshelman delivers to the company written consents from the holders of a majority of the outstanding shares of puma common stock dr eshelman has retained cadwalader wickersham  taft llp and young conaway stargatt  taylor llp as legal counsel on this matter this press release is not a proxy statement or a consent statement nor is it a solicitation of any proxy or consent any such solicitation will be made only by a written definitive consent solicitation statement the definitive consent statement duly filed with the sec dr eshelman and the nominees have filed a preliminary consent statement the preliminary consent statement with the sec please read the preliminary consent statement carefully because it contains important information about the identity of the participants including but not limited to dr eshelman the proposals he is asking the stockholders to approve the nominees that he is proposing to be elected to serve on the companys board of directors and their respective holdings securities or otherwise direct or indirect in the company you may obtain a free copy of the preliminary consent statement and when available the definitive consent statement at the secs website wwwsecgov or by directing a request to okapi partners llc at the investor inquiries contact above certain information regarding forwardlooking statements this press release includes forwardlooking statements within the meaning of section a of the securities act of  as amended and section e of the securities exchange act of  as amended regarding among other things dr eshelman plans to distribute a definitive consent statement such forwardlooking statements involve known and unknown risks uncertainties and other factors that may cause actual results performance or achievements to be materially different from any future results performance or achievements expressed or implied by such forwardlooking statements readers are cautioned not to place undue reliance on these forwardlooking statements which speak only as of the date thereof we undertake no obligation to publicly release the result of any revisions to these forwardlooking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events contacts investorsokapi partners llcbruce goldfarb bhgoldfarbokapipartnerscomormediafinsburykal goldberg  chuck nathan  chris ryallkalgoldbergfinsburycomcharlesnathanfinsburycomchrisryallfinsburycom contacts investorsokapi partners llcbruce goldfarb bhgoldfarbokapipartnerscomormediafinsburykal goldberg  chuck nathan  chris ryallkalgoldbergfinsburycomcharlesnathanfinsburycomchrisryallfinsburycom search advanced news search advanced news search log in sign up eshelman fredric n  insider stock trading  openinsider sector all sectors group by sector aerospace agriculture automobile building business services chemical electrical energy fashion financial food  beverage fund healthcare household insurance machinery media metals mining other personal services real estate retail technology telecom transportation utility industry all industries group by industry insiders filings all purchases sales cik   address co g therapeutics inc  tw alexander drive research triangle park nc   results links secyahoogooglefinviztradingviewstockchartsstocktwitsdownload csv tc stat stk ins fil d w m q h y avg pretpwins filing date t date ticker issuerinc sector indindustry owner ost rel title t tval price l qty oc own h ry ry rm rm rw rw rd rd fd fw fm fm fm fy  gthxg therapeutics incdehealthdrugpharmaceutical preparationseshelman fredric nncdtpdi  mdcomedicines co dedehealthdrugpharmaceutical preparationseshelman fredric nnjdpmd  mdcomedicines co dedehealthdrugpharmaceutical preparationseshelman fredric nnjdpd  furxfuriex pharmaceuticals incdehealthdrugpharmaceutical preparationseshelman fredric nncdtmdi  furxfuriex pharmaceuticals incdehealthdrugpharmaceutical preparationseshelman fredric nncdtpdmd  furxfuriex pharmaceuticals incdehealthdrugpharmaceutical preparationseshelman fredric nncdtpdmd  furxfuriex pharmaceuticals incdehealthdrugpharmaceutical preparationseshelman fredric nncdtpdmd  furxfuriex pharmaceuticals incdehealthdrugpharmaceutical preparationseshelman fredric nncdtpdd  furxfuriex pharmaceuticals incdehealthdrugpharmaceutical preparationseshelman fredric nncdtpdd  furxfuriex pharmaceuticals incdehealthdrugpharmaceutical preparationseshelman fredric nncdtpdmd  furxfuriex pharmaceuticals incdehealthdrugpharmaceutical preparationseshelman fredric nncdtpdd  furxfuriex pharmaceuticals incdehealthdrugpharmaceutical preparationseshelman fredric nncdtpdd  furxfuriex pharmaceuticals incdehealthdrugpharmaceutical preparationseshelman fredric nncdtpdd  furxfuriex pharmaceuticals incdehealthdrugpharmaceutical preparationseshelman fredric nncdtpdmd  furxfuriex pharmaceuticals incdehealthdrugpharmaceutical preparationseshelman fredric nncdtpad  furxfuriex pharmaceuticals incdehealthdrugpharmaceutical preparationseshelman fredric nncdtpdmd  furxfuriex pharmaceuticals incdehealthdrugpharmaceutical preparationseshelman fredric nncdtpdmd  furxfuriex pharmaceuticals incdehealthdrugpharmaceutical preparationseshelman fredric nncdtmdi  furxfuriex pharmaceuticals incdehealthdrugpharmaceutical preparationseshelman fredric nncdtpdd  furxfuriex pharmaceuticals incdehealthdrugpharmaceutical preparationseshelman fredric nncdtpdmd  furxfuriex pharmaceuticals incdehealthdrugpharmaceutical preparationseshelman fredric nncdtpdmd  furxfuriex pharmaceuticals incdehealthdrugpharmaceutical preparationseshelman fredric nncdtpdmd  furxfuriex pharmaceuticals incdehealthdrugpharmaceutical preparationseshelman fredric nncdtpdmd  furxfuriex pharmaceuticals incdehealthdrugpharmaceutical preparationseshelman fredric nncdtpdd  furxfuriex pharmaceuticals incdehealthdrugpharmaceutical preparationseshelman fredric nncdtpdd  furxfuriex pharmaceuticals incdehealthdrugpharmaceutical preparationseshelman fredric nncdtpdmd  furxfuriex pharmaceuticals incdehealthdrugpharmaceutical preparationseshelman fredric nncdpdmd  furxfuriex pharmaceuticals incdehealthdrugpharmaceutical preparationseshelman fredric nncdpdmd  ppdipharmaceutical product development incnchealthbiolabcommercial physical  biologieshelman fredric nncdoceosdmd  ppdipharmaceutical product development incnchealthbiolabcommercial physical  biologieshelman fredric nncdoceosdmd  ppdipharmaceutical product development incnchealthbiolabcommercial physical  biologieshelman fredric nncdoceosd  ppdipharmaceutical product development incnchealthbiolabcommercial physical  biologieshelman fredric nncdoceosd  ppdipharmaceutical product development incnchealthbiolabcommercial physical  biologieshelman fredric nncdoceosd  ppdipharmaceutical product development incnchealthbiolabcommercial physical  biologieshelman fredric nncdoceosdd  ppdipharmaceutical product development incnchealthbiolabcommercial physical  biologieshelman fredric nncdoceosd  ppdipharmaceutical product development incnchealthbiolabcommercial physical  biologieshelman fredric nncdoceosdd  ppdipharmaceutical product development incnchealthbiolabcommercial physical  biologieshelman fredric nncdoceosdd  ppdipharmaceutical product development incnchealthbiolabcommercial physical  biologieshelman fredric nncdoceosdmd  ppdipharmaceutical product development incnchealthbiolabcommercial physical  biologieshelman fredric nncdoceosd  ppdipharmaceutical product development incnchealthbiolabcommercial physical  biologieshelman fredric nncdoceosd  ppdipharmaceutical product development incnchealthbiolabcommercial physical  biologieshelman fredric nncdoceosdd  ppdipharmaceutical product development incnchealthbiolabcommercial physical  biologieshelman fredric nncdoceosd  ppdipharmaceutical product development incnchealthbiolabcommercial physical  biologieshelman fredric nncdoceosdd  ppdipharmaceutical product development incnchealthbiolabcommercial physical  biologieshelman fredric nncdoceosd  ppdipharmaceutical product development incnchealthbiolabcommercial physical  biologieshelman fredric nncdoceosd  ppdipharmaceutical product development incnchealthbiolabcommercial physical  biologieshelman fredric nncdoceosdd  ppdipharmaceutical product development incnchealthbiolabcommercial physical  biologieshelman fredric nncdoceosdd  ppdipharmaceutical product development incnchealthbiolabcommercial physical  biologieshelman fredric nncdoceosdd  ppdipharmaceutical product development incnchealthbiolabcommercial physical  biologieshelman fredric nncdoceosdd  ppdipharmaceutical product development incnchealthbiolabcommercial physical  biologieshelman fredric nncdoceosdd  ppdipharmaceutical product development incnchealthbiolabcommercial physical  biologieshelman fredric nncdoceosd  ppdipharmaceutical product development incnchealthbiolabcommercial physical  biologieshelman fredric nncdoceosdd  ppdipharmaceutical product development incnchealthbiolabcommercial physical  biologieshelman fredric nncdoceosd  ppdipharmaceutical product development incnchealthbiolabcommercial physical  biologieshelman fredric nncdoceosdd  ppdipharmaceutical product development incnchealthbiolabcommercial physical  biologieshelman fredric nncdoceosd  ppdipharmaceutical product development incnchealthbiolabcommercial physical  biologieshelman fredric nncdoceosd  ppdipharmaceutical product development incnchealthbiolabcommercial physical  biologieshelman fredric nncdoceosdd  ppdipharmaceutical product development incnchealthbiolabcommercial physical  biologieshelman fredric nncdoceosdd  ppdipharmaceutical product development incnchealthbiolabcommercial physical  biologieshelman fredric nncdoceosdd  ppdipharmaceutical product development incnchealthbiolabcommercial physical  biologieshelman fredric nncdoceosd  ppdipharmaceutical product development incnchealthbiolabcommercial physical  biologieshelman fredric nncdoceosd  ppdipharmaceutical product development incnchealthbiolabcommercial physical  biologieshelman fredric nncdoceosdd  ppdipharmaceutical product development incnchealthbiolabcommercial physical  biologieshelman fredric nncdoceosd  ppdipharmaceutical product development incnchealthbiolabcommercial physical  biologieshelman fredric nncoceosdd  ppdipharmaceutical product development incnchealthbiolabcommercial physical  biologieshelman fredric nncdoceosd  ppdipharmaceutical product development incnchealthbiolabcommercial physical  biologieshelman fredric nncdoceosd  ppdipharmaceutical product development incnchealthbiolabcommercial physical  biologieshelman fredric nncdoceosd  ppdipharmaceutical product development incnchealthbiolabcommercial physical  biologieshelman fredric nncdoceosd  ppdipharmaceutical product development incnchealthbiolabcommercial physical  biologieshelman fredric nncdoceosmd  ppdipharmaceutical product development incnchealthbiolabcommercial physical  biologieshelman fredric nncdoceomdd dderivative transaction in filing usually option exercise mmultiple transactions in filing earliest reported transaction date and weighted average transaction price aamended filing eerror detected in filing s  salesale of securities on an exchange or to another person s  saleoesale of securities on an exchange or to another person after option exercise f  taxpayment of exercise price or tax liability using portion of securities received from the company p  purchasepurchase of securities on an exchange or from another person return to top contact copyright   openinsidercom all rights reserved about us  eshelman ventures llc of wilmington nc eshelman ventures llc toggle navigation eshelman ventures llc about us investment criteria portfolio press contact about us fred eshelman is the founder of eshelman ventures llc an investment company primarily interested in private healthcare companies he often serves on the boards of portfolio companies previously he founded and served as ceo and executive chairman of pharmaceutical product development ppdi nasdaq prior to the sale of the company to private equity interests after ppd he served as founding chairman and largest shareholder of furiex pharmaceuticals furx nasdaq a company which licensed and rapidly developed new medicines furiex was sold to forest labsactavis in july  he is chairman of the medicines company mdco nasdaq and recently joined the board of valeant pharmaceuticals vrx his career has also included positions as senior vice president development and board member of the former glaxo inc as well as various management positions with beecham laboratories and boehringer mannheim pharmaceuticals eshelman has served on the executive committee of the medical foundation of north carolina was on the board of trustees for uncw and in  was appointed by the nc general assembly to serve on the board of governors for the states multicampus university system as well as the nc biotechnology center in addition he chairs the board of visitors for the school of pharmacy at uncch which was recently named the number one pharmacy school in the us in may  the school was named the unc eshelman school of pharmacy in recognition of his many contributions to the school and the profession eshelman has received many awards including the davie and distinguished service awards from unc and outstanding alumnus from both the unc and university of cincinnati schools of pharmacy as well as the nc entrepreneur hall of fame award and the nc business hall of fame he received the doctor of pharmacy from the university of cincinnati completed a residency at cincinnati general hospital and a bs in pharmacy from uncch he completed the opm program at harvard business school quick links home about us investment criteria portfolio press contact address  n rd street suite  wilmington nc  phone     copyright   eshelman ventures llc all rights reservedweb design  hosting by wilmington design co fredric n eshelman  wilmington nc  intelius sign in we found fredric n eshelman in wilmington nc fredric n eshelman intelius found that fredric n eshelman is a male between  and  years old from wilmington nc we have connected them to  addresses  phones and  relatives or associates also known as fred neville eshelman get report now age fredric n eshelman is in his s fredric has lived in wilmington nc wrightsville beach nc morrisville nc fredrics relatives donna clements robert eshelman kimberly eshelman april eshelman fredric n eshelman zodiac signcancer gendermale professional status executive chairman at ppd inc get report now want to know more about fredric get a comprehensive background report find full phone numbers and other contact information when available all from billions of available public records continue below for more details about fredric or use our people search engine to find others get background check on fredric n eshelman get a criminal check on fredric n eshelman get a public record report on fredric n eshelman get a people search report on fredric n eshelman fredric n eshelmans contact information known cities lived in find out where fredric n eshelman has lived as well as fredric n eshelmans phone numbers and email addresses fredric n eshelman has lived in  states north carolina address for fredric n eshelman  t r wilmington nc has lived in wilmington nc wrightsville beach nc get full address report phone numbers associated with fredric n eshelman    wilmington nc    wilmington nc    morrisville nc get full phone report email addresses associated with fredric n eshelman fdcom fncom fncom get email report fredric n eshelmans education information known schools attended learn about fredric n eshelmans academic history find out which schools fredric n eshelman attended the dates attended as well as the degrees fredric n eshelman received the following data is not guaranteed for accuracy and should not be used for employment insurance credit eligibility or for any other purpose covered under the fair credit reporting act fredric n eshelman has attended  schools university of north carolina at chapel hill fredric n eshelman has a bachelors degree in pharmacy central high school  –  fredric n eshelmans professional information information regarding fredric n eshelmans professional history find out previous places fredric n eshelman has worked as well as dates employed the following data is not guaranteed for accuracy and should not be used for employment insurance credit eligibility or for any other purpose covered under the fair credit reporting act fredric n eshelman has worked at  places company ppd inc title executive chairman company ppd inc title chief executive officer fredric n eshelmans experience title executive chairman company ppd inc job details company size  mil to less than  bil  employee range  to less than  ppd is a leading global contract research organization providing drug discovery development and lifecycle management services our clients and partners include pharmaceutical biotechnology medical device academic and government organizations with offices in  countries and more than  professionals worldwide ppd applies innovative technologies therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their rd investments title chief executive officer company ppd inc job details company size  mil to less than  mil  employee range  to less than  ppd is a leading global contract research organization providing drug discovery development and lifecycle management services our clients and partners include pharmaceutical biotechnology medical device academic and government organizations with offices in  countries and more than  professionals worldwide ppd applies innovative technologies therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their rd investments additional professional information on fredric n eshelman see fredric n eshelmans linkedin profile fredric n eshelmans social network and potential email matches find out potential social network profiles and potential email usernamed for fredric n eshelman fredric n eshelmans known social networks and potential email matches find all of fredric n eshelmans social network profiles get full report search social networks including facebook linkedin myspace google twitter yahoo jigsaw zoominfo and more potential email matches fredric eshelman username matches fredriceshelman eshelmanfredric fredriceshelman eshelmanfredric fredriceshelman eshelmanfredric fredriceshelman eshelmanfredric feshelman popular email services gmailcom aolcom yahoocom comcastnet hotmailcom msncom rocketmailcom attnet sbcglobalnet ymailcom facebookcom mailcom bellsouthnet livecom earthlinknet coxnet prodigynet mecom peoplepccom junocom rediffmailcom mindspringcom comcastcom charternet outlookcom all trademarks product names company names or logos on this page are the property of their respective owners related people searches f eshelman intelius is a leading provider of public data about people and their connections to others intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fair credit reporting act fcra this site should not be used to determine an individual’s eligibility for credit insurance employment housing or any other purpose covered by the fcra for employment or tenant screening services please visit our partner talentwise about us site map about our reports blog help contact us   –  peopleconnect inc dba intelius all rights reserved privacy policy  updated terms of service  updated what is the fcra the fair credit reporting act fcra is a federal law that promotes the accuracy fairness and privacy of information in the files of consumer reporting agencies intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fcra intelius reports cannot be used for background checks related to consumer credit insurance employment housing or any other purpose prohibited under the fcra you may not use any information obtained from intelius for any purpose covered by the fcra find out more about the fcra here